Betamethasone Administration in Late Preterm Period: Updated Guidelines
Yes, the updated 2021 SMFM guidelines recommend offering betamethasone up to 36 weeks + 6 days for patients at high risk of delivery within 7 days, with consideration even for those expected to deliver in less than 12 hours. 1
Current Guideline Recommendations
The Society for Maternal-Fetal Medicine (SMFM) 2021 Consult Series #58 provides clear direction:
Primary recommendation (GRADE 1A): Offer a single course of betamethasone (2 doses of 12 mg IM, 24 hours apart) to patients with singleton pregnancies between 34 0/7 and 36 6/7 weeks who are at high risk of preterm birth within the next 7 days 1
Extended consideration (GRADE 2C): Betamethasone may be considered even for patients expected to deliver in <12 hours, though this is a weaker recommendation based on populations not included in the original ALPS trial 1
Application to Severe Preeclampsia at 36 Weeks
For your specific scenario of severe preeclampsia at 36 weeks:
Betamethasone should be offered if delivery is not anticipated within 12 hours, as this patient meets the core inclusion criteria (singleton, 36 0/7 to 36 6/7 weeks, high risk of delivery within 7 days). The benefit of reducing respiratory morbidity outweighs risks in this population 1.
Key Clinical Benefits
The ALPS trial demonstrated significant reductions in:
- Respiratory support needs (11.6% vs 14.4%; RR 0.80) 1
- Severe respiratory morbidity (8.1% vs 12.1%; RR 0.67) 1
- Primarily transient tachypnea of the newborn 2
Important Caveats and Contraindications
Do NOT give betamethasone if:
- Pregestational diabetes mellitus is present - this is a GRADE 1C recommendation against use due to increased risk of neonatal hypoglycemia 1
- Low likelihood of delivery before 37 weeks (GRADE 1B against) 1
Counseling Requirements
Patients must be counseled that:
- Long-term neurodevelopmental effects remain uncertain 1
- Neonatal hypoglycemia may increase (though not associated with prolonged hospitalization) 2
- The primary benefit is reduction in transient respiratory conditions, not prevention of all prematurity complications 3
Practical Implementation
Timing considerations:
- Ideally administer when delivery is anticipated within 7 days but NOT within 12 hours
- If delivery is imminent (<12 hours), betamethasone may still be considered but evidence is weaker (GRADE 2C) 1
- Single course only - do not repeat in late preterm period 1
Common pitfall to avoid: Do not administer betamethasone to patients with gestational or pregestational diabetes in the late preterm period, as the risk of severe neonatal hypoglycemia outweighs respiratory benefits 1.
The 2021 guidelines represent an expansion from the older 2017 ACOG recommendations 4, which were more conservative. The current evidence base from the ALPS trial supports this broader application up to 36 6/7 weeks 1.